Alpha 2.0
Login Register
» Authors » Charla Andrews

Charla Andrews

Explore the profile of Charla Andrews including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 2480
Followers 0
Related Specialties
General Medicine
Infectious Diseases
Toxicology
Top 10 Co-Authors
Supachai Rerks-Ngarm
Jerome H Kim
Nelson L Michael
Sorachai Nitayaphan
Richard A Koup
John R Mascola
Merlin L Robb
Robert T Bailer
Jaranit Kaewkungwal
Punnee Pitisuttithum
Published In
PLoS One
Lancet
Toxicol Sci
J Infect Dis
Lancet Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial
Mwesigwa B, Houser K, Hofstetter A, Ortega-Villa A, Naluyima P, Kiweewa F, et al.
Lancet Infect Dis . 2023 Aug; 23(12):1408-1417. PMID: 37544326
Background: Sudan Ebola virus can cause severe viral disease, with an average case fatality rate of 54%. A recent outbreak of Sudan Ebola virus in Uganda caused 55 deaths among...
2.
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial
Hamer M, Houser K, Hofstetter A, Ortega-Villa A, Lee C, Preston A, et al.
Lancet . 2023 Jan; 401(10373):294-302. PMID: 36709074
Background: WHO has identified Marburg virus as an emerging virus requiring urgent vaccine research and development, particularly due to its recent emergence in Ghana. We report results from a first-in-human...
3.
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial
Coates E, Edupuganti S, Chen G, Happe M, Strom L, Widge A, et al.
Lancet Infect Dis . 2022 May; 22(8):1210-1220. PMID: 35568049
Background: Western (WEEV), eastern (EEEV), and Venezuelan (VEEV) equine encephalitis viruses are mosquito-borne pathogens classified as potential biological warfare agents for which there are currently no approved human vaccines or...
4.
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial
Chen G, Coates E, Plummer S, Carter C, Berkowitz N, Conan-Cibotti M, et al.
JAMA . 2020 Apr; 323(14):1369-1377. PMID: 32286643
Importance: Chikungunya virus (CHIKV) is a mosquito-borne Alphavirus prevalent worldwide. There are currently no licensed vaccines or therapies. Objective: To evaluate the safety and tolerability of an investigational CHIKV virus-like...
5.
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study
Gaudinski M, Coates E, Novik L, Widge A, Houser K, Burch E, et al.
Lancet . 2019 Jan; 393(10174):889-898. PMID: 30686586
Background: mAb114 is a single monoclonal antibody that targets the receptor-binding domain of Ebola virus glycoprotein, which prevents mortality in rhesus macaques treated after lethal challenge with Zaire ebolavirus. Here...
6.
HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial
Prentice H, Ehrenberg P, Baldwin K, Geretz A, Andrews C, Nitayaphan S, et al.
Immunogenetics . 2014 Apr; 66(5):299-310. PMID: 24682434
RV144 is the first phase 3 HIV vaccine clinical trial to demonstrate efficacy. This study consisted of more than 8,000 individuals in each arm of the trial, representing the four...
7.
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines
Chung A, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, et al.
Sci Transl Med . 2014 Mar; 6(228):228ra38. PMID: 24648341
The human phase 2B RV144 ALVAC-HIV vCP1521/AIDSVAX B/E vaccine trial, held in Thailand, resulted in an estimated 31.2% efficacy against HIV infection. By contrast, vaccination with VAX003 (consisting of only...
8.
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection
Zolla-Pazner S, deCamp A, B Gilbert P, Williams C, Yates N, Williams W, et al.
PLoS One . 2014 Feb; 9(2):e87572. PMID: 24504509
Unlabelled: In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variable regions 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 were an inverse correlate...
9.
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial
Zolla-Pazner S, deCamp A, Cardozo T, Karasavvas N, Gottardo R, Williams C, et al.
PLoS One . 2013 Jan; 8(1):e53629. PMID: 23349725
The RV144 clinical trial of a prime/boost immunizing regimen using recombinant canary pox (ALVAC-HIV) and two gp120 proteins (AIDSVAX B and E) was previously shown to have a 31.2% efficacy...
10.
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120
Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer R, et al.
AIDS Res Hum Retroviruses . 2012 Oct; 28(11):1444-57. PMID: 23035746
The Thai Phase III clinical trial (RV144) showed modest efficacy in preventing HIV-1 acquisition. Plasma collected from HIV-1-uninfected trial participants completing all injections with ALVAC-HIV (vCP1521) prime and AIDSVAX B/E...